SHANGHAI, Nov. 6, 2012 /PRNewswire/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2012, on November 20, 2012. Management will host a conference call to discuss the results at 8:00AM U.S. Eastern Time on November 20, 2012 ( 9:00PM Beijing Time on November 20, 2012).
Mr. Michael Xin Hui, founder and Chief Executive Officer, and Mr. William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.
Dial-in details for the live conference call are as follows:International: +1-718-354-1231 United States: +1-866-519-4004 United Kingdom: 080-8234-6646 Hong Kong: +852-2475-0994 Passcode: SHP A live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com. A telephone replay of the call will be available for seven days from November 20, 2012, 11:00AM U.S. Eastern Time, to November 27, 2012, 11:59PM U.S. Eastern Time. The dial-in details for the replay are as follows: International: +61-2-8199-0299Passcode: 68445369 ABOUT SHANGPHARMA CORPORATION ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. For further information, please contact:
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV